Skip to main content

Clinical

RSS  

Articles

  • Pharmacology Update: Alefacept (Amevive) for Psoriasis Treatment

    Alefacept is a new biological agent for the treatment of moderate-to-severe plaque psoriasis. The drug, which targets T lymphocytes, is a fusion protein combining the binding site of lymphocyte function-associated antigen-3 and the Fc portion of human IgG1.
  • Clinical Briefs in Primary Care

    Ice Cream-Evoked Headaches Study: A Randomized Trial of Accelerated vs Cautious Eating; Treatment of Antidepressant-Associated Sexual Dysfunction with Sildenafil; Prophylactic Treatment of Migraine with an Angiotensin II Receptor Blocker; Syncope, Driving Recommendations, and Clinical Reality: Survey of Patients; ACE + ARB for Diabetic and Hypersensitive Neuropathy; Action and Efficacy of a Combination of Calcipotriene and Betamethasone Dipropionate in the Treatment of Psoriasis
  • Maintain confidential care for adolescents

    Your practice includes confidential care for adolescents, including provision of contraceptives and testing/treatment for sexually transmitted diseases (STDs). But are your office staff communicating the confidentiality of this information correctly to prospective teen patients? If they are not, adolescents may fail to access these important services.
  • The Pill and bone health: What is the impact?

    Combined oral contraceptives (OCs) help decrease a womans risk for epithelial ovarian cancer and endometrial cancer, reduce her risk of pelvic inflammatory disease and ectopic pregnancy, and lessen menstrual cramps and pain. But what is their impact on bone mineral density (BMD)?
  • Ask the Experts: Answers to questions on OC use, DMPA impact

    Whats the impact of concomitant medications on combined oral contraceptives (OCs)?
  • CTU Updates

    Enter abstracts for ARHP annual conference; New payment options announced for Mirena
  • Hormone therapy: Make decisions on a balanced risk-to-benefit basis

    Family planning clinicians have found their care of postmenopausal women has changed dramatically since the July 2002 cessation of the estrogen/progestin arm of the Womens Health Initiative (WHI). The estrogen/progestin arm of the landmark study was halted after findings showed that the overall health risk, particularly of cardiovascular disease and breast cancer, from taking estrogens with progestin was greater than the benefits of lowering the risk of colon cancer and bone fractures.
  • Use the web for hormone therapy information

    Check out the following Internet resources for more information on hormone therapy.
  • Getting men on board: one facility’s approach

    If the number of men on your patient rosters is low, take a look at the approach used by Planned Parenthood of San Antonio and South Central Texas. In the first year of its marketing initiative, the number of its male patients nearly doubled from 2% to 3.7% of total patients served.
  • Norovirus Infection

    Noroviruses are a frequent cause of acute gastroenteritis. During the last 2 months of 2002 in a single health district in Washington state, 10 outbreaks of acute gastroenteritis attributable to norovirus were investigated. These events affected 354 patients in 6 long-term care facilities, a community hospital, an outpatient clinic, and the county jail.